$QURE

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.

UniQure faces securities fraud lawsuit alleging false FDA approval and BLA timeline claims. Investors in stock between September-October 2025 can join class action by April 2026 deadline.

uniQure faces class action lawsuit alleging misleading statements about pivotal study design and FDA approval prospects. Shareholders have until April 13, 2026 to join.

Hagens Berman investigates $QURE for misrepresenting FDA interactions on gene therapy AMT-130. Stock crashed 49% after FDA publicly rebuked company's data claims.

Class action lawsuit filed against $UQRR alleging materially false statements about FDA approval and BLA timeline delays. Investors urged to join by April 13, 2026 deadline.

Shareholder lawsuits target $KD and $QURE over alleged disclosure violations, with lead plaintiff applications due April 13, 2026. Affected investors may pursue recovery.

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.

Levi & Korsinsky sued $QURE over false FDA statements. Investors who lost money Sept-Oct 2025 can claim damages by April 13, 2026.

U.S. stock futures tumbled as crude oil surged 13-15% amid Iran tensions. Hims & Hers soared 49% on Novo Nordisk settlement; UniQure gained 36% on FDA clarity.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

uniQure faces securities lawsuit for allegedly misrepresenting Huntington's study design approval and downplaying BLA delays. Investors must act by April 13, 2026.

Class action lawsuit filed against $QURE over alleged misstatements about AMT-130 gene therapy FDA approval status. Stock plunged 49% after FDA reversed position on Phase I/II data adequacy.

uniQure faces shareholder lawsuit alleging false statements on FDA approval and study design. Lead plaintiff deadline: April 13, 2026.

uniQure faces securities class action lawsuit alleging misstatements about Pivotal Study design and FDA approval. Lead plaintiff deadline: April 13, 2026.

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.

Rosen Law Firm urges Paysafe investors to join securities class action alleging disclosure failures, with April 7, 2026 lead plaintiff deadline.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.